Question explored with the scientific record
Does metformin reduce long COVID symptoms, and what did the randomized trials find?
The short version: metformin cut long COVID risk when taken during acute infection, but no trial has tested it as a treatment for people who already have long COVID.
The key trial is COVID-OUT, a blinded, placebo-controlled randomized trial in adults with overweight or obesity, confirmed infection within 3 days, and symptoms within 7 days [1]. Metformin did not hit the primary outcome, hypoxemia [1]. But in secondary analyses it cut long COVID incidence by 42% relative to placebo and reduced viral load 3.6-fold [1]. That is a real randomized signal, but it is a secondary endpoint, not the pre-specified primary one, and the viral load result came from a preprint [1].
The 2025 scoping review of long COVID treatments is blunt about the gap: metformin has "some acute-phase data and a 2023 preventive study suggesting reduced PASC incidence when used around acute infection," but there is "insufficient evidence for efficacy in established PASC" [2]. It calls for trials focused on PASC patients to confirm efficacy [2]. That is the honest state of the evidence.
| Question | What the trials show |
|---|---|
| Metformin during acute infection | 42% relative drop in long COVID incidence, secondary endpoint [1] |
| Metformin for established long COVID | No trial evidence; insufficient [2] |
| Primary trial outcome (hypoxemia) | Not significant [1] |
My call: if you already have long COVID, the randomized evidence does not show metformin helps you. If you are in the first week of infection, the signal is real but secondary. Confidence: moderate on the acute-prevention signal, low on any treatment claim for established long COVID.
Sources used 2
-
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults
This narrative review concludes that metformin, an FDA-approved geroscience candidate, may improve influenza and SARS-CoV-2 infection outcomes and vaccination responses in older adults by targeting aging hallmarks and immune dysregulation.
DOI: 10.3389/fragi.2023.1272336 -
Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review
A scoping review synthesizing nine potential pharmacologic options for post-acute sequelae of COVID-19 (PASC), summarizing mechanisms, evidence, and gaps, and concluding that heterogeneity of symptoms necessitates standardized, targeted trials.
DOI: 10.1186/s12879-025-11131-x